{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T18:56:05Z","timestamp":1791658565722,"version":"4.3.4"},"reference-count":180,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004901","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de Minas Gerais","doi-asserted-by":"publisher","award":["APQ-04596-25"],"award-info":[{"award-number":["APQ-04596-25"]}],"id":[{"id":"10.13039\/501100004901","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["406765\/2021-9"],"award-info":[{"award-number":["406765\/2021-9"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["407075\/2018-6"],"award-info":[{"award-number":["407075\/2018-6"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005285","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de Goi\u00e1s","doi-asserted-by":"publisher","award":["AUX2024361000034"],"award-info":[{"award-number":["AUX2024361000034"]}],"id":[{"id":"10.13039\/501100005285","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005742","name":"Universidade Federal De Goi\u00e1s","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005742","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Glycine is a fundamental neuroactive amino acid that serves dual roles in the central nervous system: acting as a primary inhibitory neurotransmitter via strychnine-sensitive glycine receptors and as an essential co-agonist at the N-methyl-D-aspartate (NMDA) receptor. This dual functionality is important for maintaining the excitation\u2013inhibition balance, synaptic plasticity, and network stability. The spatial and temporal availability of glycine is strictly regulated by two high-affinity, Na\n                    <jats:sup>+<\/jats:sup>\n                    \/Cl\n                    <jats:sup>\u2212<\/jats:sup>\n                    -dependent transporters: GlyT1 (SLC6A9) and GlyT2 (SLC6A5). These transporters exhibit distinct cellular distributions and functional specializations. GlyT1 is predominantly expressed in astrocytes and specific neuronal populations, where it buffers ambient glycine levels to modulate NMDA receptor activity. In contrast, GlyT2 is primarily localized to presynaptic terminals of glycinergic neurons, where it facilitates vesicular refilling essential for inhibitory signaling. This review provides a comprehensive overview of glycine metabolism, the structural biology and transport cycles of SLC6 glycine transporters, and the neuroanatomical framework of GlyT1 function. We further synthesize pharmacological advances in GlyT1 inhibition, evaluating both sarcosine-derived and non-sarcosine inhibitors, such as NFPS (ALX-5407), bitopertin, and iclepertin. The clinical and preclinical evidence for GlyT1 as a therapeutic target in psychiatric, neurological, and neurodegenerative disorders is critically assessed. Finally, we address key translational challenges, including dosing constraints, compensatory mechanisms, and SLC6 family selectivity, while highlighting the potential of structure-guided design to refine GlyT1-targeted therapies.\n                  <\/jats:p>","DOI":"10.1007\/s00210-026-05276-y","type":"journal-article","created":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T02:53:57Z","timestamp":1776135237000},"page":"12983-13008","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["GlyT1 (SLC6A9) inhibition in neurological and psychiatric disorders"],"prefix":"10.1007","volume":"399","author":[{"given":"Daniel Pereira","family":"Cavalcante","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo Almeida","family":"Carvalho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ant\u00f4nio \u00cdtalo Santos","family":"Nunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda Rodrigues","family":"Quintanilha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas Rodrigues Couto","family":"Nascimento","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Caixeta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henning","family":"Ulrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato Santiago","family":"Gomez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro Cunha Xavier","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,14]]},"reference":[{"key":"5276_CR1","doi-asserted-by":"publisher","first-page":"2837","DOI":"10.1038\/npp.2012.155","volume":"37","author":"C Achat-Mendes","year":"2012","unstructured":"Achat-Mendes C, Nic Dhonnchadha B\u00c1, Platt DM, Kantak KM, Spealman RD (2012) Glycine transporter-1 inhibition preceding extinction training inhibits reacquisition of cocaine seeking. Neuropsychopharmacology 37:2837\u20132845","journal-title":"Neuropsychopharmacology"},{"key":"5276_CR2","doi-asserted-by":"publisher","first-page":"2524","DOI":"10.1523\/JNEUROSCI.15-03-02524.1995","volume":"15","author":"R Adams","year":"1995","unstructured":"Adams R, Sato K, Shimada S, Tohyama M, Puschel A, Betz H (1995) Gene structure and glial expression of the glycine transporter GlyT1 in embryonic and adult rodents. J Neurosci 15:2524\u20132532","journal-title":"J Neurosci"},{"key":"5276_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.118826","volume":"265","author":"E Akyuz","year":"2021","unstructured":"Akyuz E, Polat AK, Eroglu E, Kullu I, Angelopoulou E, Paudel YN (2021) Revisiting the role of neurotransmitters in epilepsy: an updated review. Life Sci 265:118826","journal-title":"Life Sci"},{"key":"5276_CR4","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1016\/j.neuropharm.2011.11.008","volume":"62","author":"D Alberati","year":"2012","unstructured":"Alberati D, Moreau J-L, Lengyel J, Hauser N, Mory R, Borroni E, Pinard E, Knoflach F, Schlotterbeck G, Hainzl D (2012) Glycine reuptake inhibitor RG1678: a pharmacologic characterization of an investigational agent for the treatment of schizophrenia. Neuropharmacology 62:1152\u20131161","journal-title":"Neuropharmacology"},{"key":"5276_CR5","unstructured":"Amberg W, Lange U, Ochse M, Pohlki F, Hutchins CW, Zanze I, Li H-Q (2016) Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy. US Patent 9,365,512 B2"},{"key":"5276_CR6","doi-asserted-by":"publisher","first-page":"7503","DOI":"10.1021\/acs.jmedchem.8b00300","volume":"61","author":"W Amberg","year":"2018","unstructured":"Amberg W, Lange UE, Ochse M, Pohlki F, Behl B, Relo AL, Hornberger W, Hoft C, Mezler M, Sydor J (2018) Discovery of novel aminotetralines and aminochromanes as selective and competitive glycine transporter 1 (GlyT1) inhibitors. J Med Chem 61:7503\u20137524","journal-title":"J Med Chem"},{"key":"5276_CR7","unstructured":"Amberg W, Pohlki F, Lange U, Li H-Q, Brewer JT, Zanze I, Dietrich J, Vasudevan A, Djuric SW, Lao Y (2017) Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy. Google Patents, US Patent 9,663,435 B2"},{"key":"5276_CR8","unstructured":"Aprison MH (1990) The discovery of the neurotransmitter role of glycine. In: Glycine neurotransmission. pp 1\u201323"},{"key":"5276_CR9","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.ejphar.2003.08.074","volume":"479","author":"C Arag\u00f3n","year":"2003","unstructured":"Arag\u00f3n C, L\u00f3pez-Corcuera B (2003) Structure, function and regulation of glycine neurotransporters. Eur J Pharmacol 479:249\u2013262","journal-title":"Eur J Pharmacol"},{"key":"5276_CR10","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.tips.2005.04.007","volume":"26","author":"C Arag\u00f3n","year":"2005","unstructured":"Arag\u00f3n C, L\u00f3pez-Corcuera B (2005) Glycine transporters: crucial roles of pharmacological interest revealed by gene deletion. Trends Pharmacol Sci 26:283\u2013286","journal-title":"Trends Pharmacol Sci"},{"key":"5276_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2017.00438","volume":"10","author":"A Armbruster","year":"2018","unstructured":"Armbruster A, Neumann E, K\u00f6tter V, Hermanns H, Werdehausen R, Eulenburg V (2018) The GlyT1 inhibitor bitopertin ameliorates allodynia and hyperalgesia in animal models of neuropathic and inflammatory pain. Front Mol Neurosci 10:438","journal-title":"Front Mol Neurosci"},{"key":"5276_CR12","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1007\/s00429-013-0537-3","volume":"219","author":"RI Aroeira","year":"2014","unstructured":"Aroeira RI, Sebastiao AM, Valente CA (2014) GlyT1 and GlyT2 in brain astrocytes: expression, distribution and function. Brain Struct Funct 219:817\u2013830","journal-title":"Brain Struct Funct"},{"key":"5276_CR13","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1124\/mol.60.6.1414","volume":"60","author":"B Atkinson","year":"2001","unstructured":"Atkinson B, Bell S, De Vivo M, Kowalski L, Lechner S, Ognyanov V, Tham C-S, Tsai C, Jia J, Ashton D (2001) ALX 5407: a potent, selective inhibitor of the hGlyT1 glycine transporter. Mol Pharmacol 60:1414\u20131420","journal-title":"Mol Pharmacol"},{"key":"5276_CR14","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1517\/14728222.5.4.507","volume":"5","author":"KR Aubrey","year":"2001","unstructured":"Aubrey KR, Vandenberg RJ (2001a) Glycine transport inhibitors as potential antipsychotic drugs. Expert Opin Ther Targets 5:507\u2013518","journal-title":"Expert Opin Ther Targets"},{"key":"5276_CR15","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1038\/sj.bjp.0704381","volume":"134","author":"KR Aubrey","year":"2001","unstructured":"Aubrey KR, Vandenberg RJ (2001b) N[3-(4\u2019-fluorophenyl)-3-(4\u2019-phenylphenoxy)propyl]sarcosine (NFPS) is a selective persistent inhibitor of glycine transport. Br J Pharmacol 134:1429\u20131436","journal-title":"Br J Pharmacol"},{"issue":"2","key":"5276_CR16","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202012632","volume":"13","author":"M Bae","year":"2021","unstructured":"Bae M, Roh J, Kim Y, Kim S, Han H, Yang E, Kang H, Lee S, Kim J, Kang R (2021) SLC6A20 transporter: a novel regulator of brain glycine homeostasis and NMDAR function. EMBO Mol Med 13(2):e12632","journal-title":"EMBO Mol Med"},{"key":"5276_CR17","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1097\/ALN.0000000000000203","volume":"121","author":"F Barthel","year":"2014","unstructured":"Barthel F, Urban A, Schl\u00f6sser L, Eulenburg V, Werdehausen R, Brandenburger T, Aragon C, Bauer I, Hermanns H (2014) Long-term application of glycine transporter inhibitors acts antineuropathic and modulates spinal N-methyl-D-aspartate receptor subunit NR-1 expression in rats. Anesthesiology 121:160\u2013169","journal-title":"Anesthesiology"},{"key":"5276_CR18","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1007\/s00702-020-02247-2","volume":"127","author":"F Beaudry","year":"2020","unstructured":"Beaudry F, Huot P (2020) The MPTP-lesioned marmoset model of Parkinson\u2019s disease: proposed efficacy thresholds that may potentially predict successful clinical trial results. J Neural Transm 127:1343\u20131358","journal-title":"J Neural Transm"},{"key":"5276_CR19","doi-asserted-by":"publisher","first-page":"15730","DOI":"10.1073\/pnas.95.26.15730","volume":"95","author":"R Bergeron","year":"1998","unstructured":"Bergeron R, Meyer TM, Coyle JT, Greene RW (1998) Modulation of N-methyl-D-aspartate receptor function by glycine transport. Proc Natl Acad Sci USA 95:15730\u201315734","journal-title":"Proc Natl Acad Sci USA"},{"key":"5276_CR20","doi-asserted-by":"crossref","unstructured":"Betz H, Harvey RJ, Schloss P (2001) Structures, diversity and pharmacology of glycine receptors and transporters. Pharmacology of GABA and glycine neurotransmission. Springer pp 375\u2013401","DOI":"10.1007\/978-3-642-56833-6_16"},{"key":"5276_CR21","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s00213-008-1289-2","volume":"202","author":"MD Black","year":"2009","unstructured":"Black MD, Varty GB, Arad M, Barak S, De Levie A, Boulay D, Pichat P, Griebel G, Weiner I (2009) Procognitive and antipsychotic efficacy of glycine transport 1 inhibitors (GlyT1) in acute and neurodevelopmental models of schizophrenia: latent inhibition studies in the rat. Psychopharmacology 202:385\u2013396","journal-title":"Psychopharmacology"},{"key":"5276_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2016.00026","volume":"9","author":"D Boison","year":"2016","unstructured":"Boison D (2016) The biochemistry and epigenetics of epilepsy: focus on adenosine and glycine. Front Mol Neurosci 9:26","journal-title":"Front Mol Neurosci"},{"key":"5276_CR23","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/0896-6273(93)90201-2","volume":"10","author":"B Borowsky","year":"1993","unstructured":"Borowsky B, Mezey \u00c9, Hoffman BI (1993) Two glycine transporter variants with distinct localization in the CNS and peripheral tissues are encoded by a common gene. Neuron 10:851\u2013863","journal-title":"Neuron"},{"key":"5276_CR24","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.tins.2023.05.002","volume":"46","author":"S Bossi","year":"2023","unstructured":"Bossi S, Pizzamiglio L, Paoletti P (2023) Excitatory GluN1\/GluN3A glycine receptors (eGlyRs) in brain signaling. Trends Neurosci 46:667\u2013681","journal-title":"Trends Neurosci"},{"key":"5276_CR25","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.pbb.2008.06.009","volume":"91","author":"D Boulay","year":"2008","unstructured":"Boulay D, Pichat P, Dargazanli G, Estenne-Bouhtou G, Terranova JP, Rogacki N, Stemmelin J, Coste A, Lanneau C, Desvignes C (2008) Characterization of SSR103800, a selective inhibitor of the glycine transporter-1 in models predictive of therapeutic activity in schizophrenia. Pharmacol Biochem Behav 91:47\u201358","journal-title":"Pharmacol Biochem Behav"},{"key":"5276_CR26","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1038\/npp.2009.144","volume":"35","author":"D Boulay","year":"2010","unstructured":"Boulay D, Bergis O, Avenet P, Griebel G (2010) The glycine transporter-1 inhibitor SSR103800 displays a selective and specific antipsychotic-like profile in normal and transgenic mice. Neuropsychopharmacology 35:416\u2013427","journal-title":"Neuropsychopharmacology"},{"key":"5276_CR27","first-page":"591","volume":"10","author":"TM Bridges","year":"2008","unstructured":"Bridges TM, Williams R, Lindsley CW (2008) Design of potent GlyT1 inhibitors: in vitro and in vivo profiles. Curr Opin Mol Ther 10:591\u2013601","journal-title":"Curr Opin Mol Ther"},{"key":"5276_CR28","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1111\/j.1476-5381.2012.01975.x","volume":"167","author":"S Br\u00f6er","year":"2012","unstructured":"Br\u00f6er S, Gether U (2012) The solute carrier 6 family of transporters. Br J Pharmacol 167:256\u2013278","journal-title":"Br J Pharmacol"},{"key":"5276_CR29","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1016\/S0960-894X(01)00355-9","volume":"11","author":"A Brown","year":"2001","unstructured":"Brown A, Carlyle I, Clark J, Hamilton W, Gibson S, McGarry G, McEachen S, Rae D, Thorn S, Walker G (2001) Discovery and SAR of org 24598\u2014a selective glycine uptake inhibitor. Bioorg Med Chem Lett 11:2007\u20132009","journal-title":"Bioorg Med Chem Lett"},{"key":"5276_CR30","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/S2215-0366(16)30344-3","volume":"3","author":"D Bugarski-Kirola","year":"2016","unstructured":"Bugarski-Kirola D, Iwata N, Sameljak S, Reid C, Blaettler T, Millar L, Marques TR, Garibaldi G, Kapur S (2016) Efficacy and safety of adjunctive bitopertin versus placebo in patients with suboptimally controlled symptoms of schizophrenia treated with antipsychotics: results from three phase 3, randomised, double-blind, parallel-group, placebo-controlled, multicentre studies in the SearchLyte clinical trial programme. Lancet Psychiatry 3:1115\u20131128","journal-title":"Lancet Psychiatry"},{"key":"5276_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2021.103539","volume":"25","author":"J Cappelli","year":"2022","unstructured":"Cappelli J, Khacho P, Wang B, Sokolovski A, Bakkar W, Raymond S, Ahlskog N, Pitney J, Wu J, Chudalayandi P, Wong AYC, Bergeron R (2022) Glycine-induced NMDA receptor internalization provides neuroprotection and preserves vasculature following ischemic stroke. iScience 25:103539","journal-title":"iScience"},{"key":"5276_CR32","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.neuropharm.2008.06.075","volume":"56","author":"JWA Carlezon","year":"2009","unstructured":"Carlezon JWA, Thomas MJ (2009) Biological substrates of reward and aversion: a nucleus accumbens activity hypothesis. Neuropharmacology 56:122\u2013132","journal-title":"Neuropharmacology"},{"key":"5276_CR33","doi-asserted-by":"publisher","first-page":"2742","DOI":"10.1038\/npp.2014.4","volume":"39","author":"S Castner","year":"2014","unstructured":"Castner S, Murthy N, Ridler K, Herdon H, Roberts B, Weinzimmer D, Huang Y, Zheng M, Rabiner E, Gunn R (2014) Relationship between glycine transporter 1 inhibition as measured with positron emission tomography and changes in cognitive performances in nonhuman primates. Neuropsychopharmacology 39:2742\u20132749","journal-title":"Neuropsychopharmacology"},{"key":"5276_CR34","doi-asserted-by":"publisher","unstructured":"Cavalcante DP, dos Santos Nunes A\u00cd, Silva ER, de Carvalho GA, Chiarelli RA, Oliveira-Lima OC, Leoncini GO, Ulrich H, Gomez RS, Pinto MCX (2024) GlyT1 inhibition promotes neuroprotection in the middle cerebral artery occlusion model through the activation of GluN2A-containing NMDAR. Exp Neurol p 115006. https:\/\/doi.org\/10.1016\/j.expneurol.2024.115006","DOI":"10.1016\/j.expneurol.2024.115006"},{"key":"5276_CR35","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1111\/adb.12049","volume":"18","author":"L Cervo","year":"2013","unstructured":"Cervo L, Di Clemente A, Orr\u00f9 A, Moro F, Cassina C, Pich EM, Corsi M, Gozzi A, Bifone A (2013) Inhibition of glycine transporter\u20101 reduces cue\u2010induced nicotine\u2010seeking, but does not promote extinction of conditioned nicotine cue responding in the rat. Addict Biol 18:800\u2013811","journal-title":"Addict Biol"},{"key":"5276_CR36","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1007\/s00213-015-3920-3","volume":"232","author":"S Chaki","year":"2015","unstructured":"Chaki S, Shimazaki T, Karasawa J-i, Aoki T, Kaku A, Iijima M, Kambe D, Yamamoto S, Kawakita Y, Shibata T (2015) Efficacy of a glycine transporter 1 inhibitor TASP0315003 in animal models of cognitive dysfunction and negative symptoms of schizophrenia. Psychopharmacology 232:2849\u20132861","journal-title":"Psychopharmacology"},{"key":"5276_CR37","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1113\/jphysiol.2014.271700","volume":"592","author":"R Chen","year":"2014","unstructured":"Chen R, Okabe A, Sun H, Sharopov S, Hanganu-Opatz IL, Kolbaev SN, Fukuda A, Luhmann HJ, Kilb W (2014) Activation of glycine receptors modulates spontaneous epileptiform activity in the immature rat hippocampus. J Physiol 592:2153\u20132168","journal-title":"J Physiol"},{"key":"5276_CR38","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1111\/jnc.12994","volume":"133","author":"Z Chen","year":"2015","unstructured":"Chen Z, Hu B, Wang F, Du L, Huang B, Li L, Qi J, Wang X (2015) Glycine bidirectionally regulates ischemic tolerance via different mechanisms including NR2A-dependent CREB phosphorylation. J Neurochem 133:397\u2013408","journal-title":"J Neurochem"},{"key":"5276_CR39","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.neuint.2012.02.007","volume":"60","author":"AM Choo","year":"2012","unstructured":"Choo AM, Geddes-Klein DM, Hockenberry A, Scarsella D, Mesfin MN, Singh P, Patel TP, Meaney DF (2012) NR2A and NR2B subunits differentially mediate MAP kinase signaling and mitochondrial morphology following excitotoxic insult. Neurochem Int 60:506\u2013516","journal-title":"Neurochem Int"},{"key":"5276_CR40","first-page":"1311","volume":"19","author":"P Chue","year":"2013","unstructured":"Chue P (2013) Glycine reuptake inhibition as a new therapeutic approach in schizophrenia: focus on the glycine transporter 1 (GlyT1). Curr Pharm Des 19:1311\u20131320","journal-title":"Curr Pharm Des"},{"key":"5276_CR41","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1080\/13543776.2018.1429408","volume":"28","author":"CL Cioffi","year":"2018","unstructured":"Cioffi CL (2018) Glycine transporter-1 inhibitors: a patent review (2011\u20132016). Expert Opin Ther Pat 28:197\u2013210","journal-title":"Expert Opin Ther Pat"},{"key":"5276_CR42","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1016\/j.bmcl.2013.01.006","volume":"23","author":"CL Cioffi","year":"2013","unstructured":"Cioffi CL, Wolf MA, Guzzo PR, Sadalapure K, Parthasarathy V, Dethe D, Maeng J-H, Carulli E, Loong DT, Fang X (2013) Design, synthesis, and SAR of N-((1-(4-(propylsulfonyl) piperazin-1-yl) cycloalkyl) methyl) benzamide inhibitors of glycine transporter-1. Bioorg Med Chem Lett 23:1257\u20131261","journal-title":"Bioorg Med Chem Lett"},{"key":"5276_CR43","doi-asserted-by":"publisher","first-page":"8473","DOI":"10.1021\/acs.jmedchem.6b00914","volume":"59","author":"CL Cioffi","year":"2016","unstructured":"Cioffi CL, Liu S, Wolf MA, Guzzo PR, Sadalapure K, Parthasarathy V, Loong DT, Maeng J-H, Carulli E, Fang X (2016) Synthesis and biological evaluation of N-((1-(4-(sulfonyl) piperazin-1-yl) cycloalkyl) methyl) benzamide inhibitors of glycine transporter-1. J Med Chem 59:8473\u20138494","journal-title":"J Med Chem"},{"key":"5276_CR44","doi-asserted-by":"publisher","first-page":"3404","DOI":"10.2174\/1568026616666160405113340","volume":"16","author":"LC Cioffi","year":"2016","unstructured":"Cioffi LC, Guzzo RP (2016) Inhibitors of glycine transporter-1: potential therapeutics for the treatment of CNS disorders. Curr Top Med Chem 16:3404\u20133437","journal-title":"Curr Top Med Chem"},{"key":"5276_CR45","doi-asserted-by":"publisher","first-page":"394","DOI":"10.2174\/157015910793358169","volume":"8","author":"MR Cleva","year":"2010","unstructured":"Cleva MR, Gass TJ, Widholm JJ, Olive FM (2010) Glutamatergic targets for enhancing extinction learning in drug addiction. Curr Neuropharmacol 8:394\u2013408","journal-title":"Curr Neuropharmacol"},{"key":"5276_CR46","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1093\/cercor\/bhh147","volume":"15","author":"B Cubelos","year":"2005","unstructured":"Cubelos B, Gim\u00e9nez C, Zafra F (2005) Localization of the GLYT1 glycine transporter at glutamatergic synapses in the rat brain. Cereb Cortex 15:448\u2013459","journal-title":"Cereb Cortex"},{"key":"5276_CR47","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/S0031-6997(24)01382-6","volume":"50","author":"W Danysz","year":"1998","unstructured":"Danysz W, Parsons CG (1998) Glycine and N-methyl-D-aspartate receptors: physiological significance and possible therapeutic applications. Pharmacol Rev 50:597\u2013664","journal-title":"Pharmacol Rev"},{"key":"5276_CR48","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1093\/jpp\/rgae051","volume":"76","author":"GA de Carvalho","year":"2024","unstructured":"de Carvalho GA, Tambwe PM, Nascimento LRC, Campos BKP, Chiareli RA, Junior GPN, Menegatti R, Gomez RS, Pinto MCX (2024) In silico evidence of bitopertin\u2019s broad interactions within the SLC6 transporter family. J Pharm Pharmacol 76:1199\u20131211","journal-title":"J Pharm Pharmacol"},{"key":"5276_CR49","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1038\/sj.npp.1300772","volume":"30","author":"R Depoort\u00e8re","year":"2005","unstructured":"Depoort\u00e8re R, Dargazanli G, Estenne-Bouhtou G, Coste A, Lanneau C, Desvignes C, Poncelet M, Heaulme M, Santucci V, Decobert M (2005) Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a potential new type of antipsychotic. Neuropsychopharmacology 30:1963\u20131985","journal-title":"Neuropsychopharmacology"},{"key":"5276_CR50","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.drugalcdep.2011.09.017","volume":"122","author":"B\u00c1N Dhonnchadha","year":"2012","unstructured":"Dhonnchadha B\u00c1N, Pinard E, Alberati D, Wettstein JG, Spealman RD, Kantak KM (2012) Inhibiting glycine transporter-1 facilitates cocaine\u2013cue extinction and attenuates reacquisition of cocaine-seeking behavior. Drug Alcohol Depend 122:119\u2013126","journal-title":"Drug Alcohol Depend"},{"key":"5276_CR51","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.pharmthera.2009.03.018","volume":"123","author":"T Dohi","year":"2009","unstructured":"Dohi T, Morita K, Kitayama T, Motoyama N, Morioka N (2009) Glycine transporter inhibitors as a novel drug discovery strategy for neuropathic pain. Pharmacol Ther 123:54\u201379","journal-title":"Pharmacol Ther"},{"key":"5276_CR52","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1038\/npp.2011.295","volume":"37","author":"DC D'souza","year":"2012","unstructured":"D\u2019souza DC, Singh N, Elander J, Carbuto M, Pittman B, De Haes JU, Sjogren M, Peeters P, Ranganathan M, Schipper J (2012) Glycine transporter inhibitor attenuates the psychotomimetic effects of ketamine in healthy males: preliminary evidence. Neuropsychopharmacology 37:1036\u20131046","journal-title":"Neuropsychopharmacology"},{"key":"5276_CR53","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.schres.2016.10.027","volume":"182","author":"E Dunayevich","year":"2017","unstructured":"Dunayevich E, Buchanan RW, Chen C-Y, Yang J, Nilsen J, Dietrich JM, Sun H, Marder S (2017) Efficacy and safety of the glycine transporter type-1 inhibitor AMG 747 for the treatment of negative symptoms associated with schizophrenia. Schizophr Res 182:90\u201397","journal-title":"Schizophr Res"},{"key":"5276_CR54","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s00213-013-3260-0","volume":"231","author":"D Eddins","year":"2014","unstructured":"Eddins D, Hamill TG, Puri V, Cannon CE, Vivian JA, Sanabria-Boh\u00f3rquez SM, Cook JJ, Morrow JA, Thomson F, Uslaner JM (2014) The relationship between glycine transporter 1 occupancy and the effects of the glycine transporter 1 inhibitor RG1678 or ORG25935 on object retrieval performance in scopolamine impaired rhesus monkey. Psychopharmacology 231:511\u2013519","journal-title":"Psychopharmacology"},{"key":"5276_CR55","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1085\/jgp.201912318","volume":"151","author":"FA Erdem","year":"2019","unstructured":"Erdem FA, Ilic M, Koppensteiner P, Go\u0142acki J, Lubec G, Freissmuth M, Sandtner W (2019) A comparison of the transport kinetics of glycine transporter 1 and glycine transporter 2. J Gen Physiol 151:1035\u20131050","journal-title":"J Gen Physiol"},{"key":"5276_CR56","doi-asserted-by":"publisher","first-page":"5350","DOI":"10.3390\/ijms23105350","volume":"23","author":"J Filarowska-Jurko","year":"2022","unstructured":"Filarowska-Jurko J, Komsta L, Smaga I, Surowka P, Marszalek-Grabska M, Grochecki P, Nizio D, Filip M, Kotlinska JH (2022) Maternal separation alters ethanol drinking and reversal learning processes in adolescent rats: the impact of sex and glycine transporter type 1 (GlyT1) inhibitor. Int J Mol Sci 23:5350","journal-title":"Int J Mol Sci"},{"key":"5276_CR57","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1152\/physiol.00030.2009","volume":"24","author":"LR Forrest","year":"2009","unstructured":"Forrest LR, Rudnick G (2009) The rocking bundle: a mechanism for ion-coupled solute flux by symmetrical transporters. Physiology 24:377\u2013386","journal-title":"Physiology"},{"key":"5276_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2021.174452","volume":"910","author":"I Frouni","year":"2021","unstructured":"Frouni I, Belliveau S, Maddaford S, Nuara SG, Gourdon JC, Huot P (2021) Effect of the glycine transporter 1 inhibitor ALX-5407 on dyskinesia, psychosis-like behaviours and parkinsonism in the MPTP-lesioned marmoset. Eur J Pharmacol 910:174452","journal-title":"Eur J Pharmacol"},{"key":"5276_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2022.175090","volume":"929","author":"I Frouni","year":"2022","unstructured":"Frouni I, Kang W, B\u00e9dard D, Belliveau S, Kwan C, Hadj-Youssef S, Bourgeois-Cayer \u00c9, Ohlund L, Sleno L, Hamadjida A (2022) Effect of glycine transporter 1 inhibition with bitopertin on parkinsonism and L-DOPA induced dyskinesia in the 6-OHDA-lesioned rat. Eur J Pharmacol 929:175090","journal-title":"Eur J Pharmacol"},{"key":"5276_CR60","doi-asserted-by":"publisher","DOI":"10.1007\/s00221-024-06815-w","author":"I Frouni","year":"2024","unstructured":"Frouni I, Kim E, Shaqfah J, B\u00e9dard D, Kwan C, Belliveau S, Huot P (2024) [3H]-NFPS binding to the glycine transporter 1 in the hemi-parkinsonian rat brain. Experimental Brain Research. https:\/\/doi.org\/10.1007\/s00221-024-06815-w","journal-title":"Experimental Brain Research"},{"key":"5276_CR61","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.neulet.2004.09.064","volume":"373","author":"L Gabernet","year":"2005","unstructured":"Gabernet L, Pauly-Evers M, Schwerdel C, Lentz M, Bluethmann H, Vogt K, Alberati D, Mohler H, Boison D (2005) Enhancement of the NMDA receptor function by reduction of glycine transporter-1 expression. Neurosci Lett 373:79\u201384","journal-title":"Neurosci Lett"},{"key":"5276_CR62","doi-asserted-by":"publisher","DOI":"10.1021\/acschemneuro.5c00039","author":"N Gapi\u0144ska","year":"2025","unstructured":"Gapi\u0144ska N, Wlaz\u0301 P, Wyska E, \u015awierczek A, Kami\u0144ski K, Jakubiec M, Abram M, Ciepiela K, Latacz G, S\u0142owik T (2025) Effect of SSR504734, a selective glycine transporter type 1 inhibitor, on seizure thresholds, neurotransmitter levels, and inflammatory markers in mice. ACS Chem Neurosci. https:\/\/doi.org\/10.1021\/acschemneuro.5c00039","journal-title":"ACS Chem Neurosci"},{"key":"5276_CR63","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/nrn1927","volume":"7","author":"JM Gidday","year":"2006","unstructured":"Gidday JM (2006) Cerebral preconditioning and ischaemic tolerance. Nat Rev Neurosci 7:437\u2013448","journal-title":"Nat Rev Neurosci"},{"key":"5276_CR64","doi-asserted-by":"publisher","first-page":"7189","DOI":"10.1073\/pnas.89.15.7189","volume":"89","author":"J Guastella","year":"1992","unstructured":"Guastella J, Brecha N, Weigmann C, Lester HA, Davidson N (1992) Cloning, expression, and localization of a rat brain high-affinity glycine transporter. Proc Natl Acad Sci USA 89:7189\u20137193","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5276_CR65","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s11064-015-1713-z","volume":"41","author":"A Hanuska","year":"2016","unstructured":"Hanuska A, Sz\u00e9n\u00e1si G, Albert M, Koles L, Varga A, Szabo A, Matyus P, Harsing LG (2016) Some operational characteristics of glycine release in rat retina: the role of reverse mode operation of glycine transporter type-1 (GlyT-1) in ischemic conditions. Neurochem Res 41:73\u201385","journal-title":"Neurochem Res"},{"key":"5276_CR66","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.ejphar.2012.04.013","volume":"685","author":"K Harada","year":"2012","unstructured":"Harada K, Nakato K, Yarimizu J, Yamazaki M, Morita M, Takahashi S, Aota M, Saita K, Doihara H, Sato Y, Yamaji T, Ni K, Matsuoka N (2012) A novel glycine transporter-1 (GlyT1) inhibitor, ASP2535 (4-[3-isopropyl-5-(6-phenyl-3-pyridyl)-4H-1,2,4-triazol-4-yl]-2,1,3-benzoxadiazole), improves cognition in animal models of cognitive impairment in schizophrenia and Alzheimer\u2019s disease. Eur J Pharmacol 685:59\u201369","journal-title":"Eur J Pharmacol"},{"key":"5276_CR67","doi-asserted-by":"publisher","first-page":"17","DOI":"10.2174\/2666082218666220126111415","volume":"18","author":"M Harhai","year":"2022","unstructured":"Harhai M, Harsing LG (2022) An overview of glycine transporter subtype 1 inhibitors under preclinical and clinical evaluation for the treatment of alcohol abuse. Current Psychiatry Research and Reviews Formerly: Current Psychiatry Reviews 18:17\u201335","journal-title":"Current Psychiatry Research and Reviews Formerly: Current Psychiatry Reviews"},{"key":"5276_CR68","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.exer.2011.10.010","volume":"94","author":"JL Harsing","year":"2012","unstructured":"Harsing JL, Albert M, Matyus P, Szenasi G (2012a) Inhibition of hypoxia-induced [3H] glycine release from chicken retina by the glycine transporter type-1 (GlyT-1) inhibitors NFPS and Org-24461. Exp Eye Res 94:6\u201312","journal-title":"Exp Eye Res"},{"key":"5276_CR69","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.2174\/092986706776360932","volume":"13","author":"JL Harsing","year":"2006","unstructured":"Harsing JL, Juranyi Z, Gacsalyi I, Tapolcsanyi P, Czompa A, Matyus P (2006) Glycine transporter type-1 and its inhibitors. Curr Med Chem 13:1017\u20131044","journal-title":"Curr Med Chem"},{"key":"5276_CR70","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/S0091-3057(02)01078-X","volume":"74","author":"JLG Harsing","year":"2003","unstructured":"Harsing JLG, Gacsalyi I, Szabo G, Schmidt E, Sziray N, Sebban C, Tesolin-Decros B, Matyus P, Egyed A, Spedding M (2003) The glycine transporter-1 inhibitors NFPS and Org 24461: a pharmacological study. Pharmacol Biochem Behav 74:811\u2013825","journal-title":"Pharmacol Biochem Behav"},{"key":"5276_CR71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1556\/APhysiol.99.2012.1.1","volume":"99","author":"LG Harsing","year":"2012","unstructured":"Harsing LG, Zsilla G, Matyus P, Nagy KM, Marko B, Gyarmati Z, Timar J (2012b) Interactions between glycine transporter type 1 (GlyT-1) and some inhibitor molecules - glycine transporter type 1 and its inhibitors (review). Acta Physiol Hung 99:1\u201317","journal-title":"Acta Physiol Hung"},{"key":"5276_CR72","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1038\/nrd3893","volume":"12","author":"RJ Harvey","year":"2013","unstructured":"Harvey RJ, Yee BK (2013) Glycine transporters as novel therapeutic targets in schizophrenia, alcohol dependence and pain. Nat Rev Drug Discov 12:866\u2013885","journal-title":"Nat Rev Drug Discov"},{"key":"5276_CR73","doi-asserted-by":"publisher","DOI":"10.1016\/j.scog.2024.100340","volume":"40","author":"PD Harvey","year":"2025","unstructured":"Harvey PD, McDonald S, Fu E, Reuteman-Fowler C (2025) Efficacy and safety of iclepertin (BI 425809) with adjunctive computerized cognitive training in patients with schizophrenia. Schizophr Res Cogn 40:100340","journal-title":"Schizophr Res Cogn"},{"key":"5276_CR74","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.neuropharm.2010.07.023","volume":"59","author":"HJ Herdon","year":"2010","unstructured":"Herdon HJ, Roberts JC, Coulton S, Porter RA (2010) Pharmacological characterisation of the GlyT-1 glycine transporter using two novel radioligands. Neuropharmacology 59:558\u2013565","journal-title":"Neuropharmacology"},{"key":"5276_CR75","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.neulet.2008.09.012","volume":"445","author":"H Hermanns","year":"2008","unstructured":"Hermanns H, Muth-Selbach U, Williams R, Krug S, Lipfert P, Werdehausen R, Braun S, Bauer I (2008) Differential effects of spinally applied glycine transporter inhibitors on nociception in a rat model of neuropathic pain. Neurosci Lett 445:214\u2013219","journal-title":"Neurosci Lett"},{"key":"5276_CR76","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1007\/s00702-009-0326-6","volume":"116","author":"MS Hernandes","year":"2009","unstructured":"Hernandes MS, Troncone LR (2009) Glycine as a neurotransmitter in the forebrain: a short review. J Neural Transm (Vienna) 116:1551\u20131560","journal-title":"J Neural Transm (Vienna)"},{"key":"5276_CR77","doi-asserted-by":"publisher","first-page":"3335","DOI":"10.1021\/acschemneuro.1c00284","volume":"12","author":"C Hoffmann","year":"2021","unstructured":"Hoffmann C, Evc\u00fcman S, Neumaier F, Zlatopolskiy BD, Humpert S, Bier D, Holschbach M, Schulze A, Endepols H, Neumaier B (2021) [18F] ALX5406: a brain-penetrating prodrug for GlyT1-specific PET imaging. ACS Chem Neurosci 12:3335\u20133346","journal-title":"ACS Chem Neurosci"},{"key":"5276_CR78","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1007\/s00213-016-4317-7","volume":"233","author":"C Hofmann","year":"2016","unstructured":"Hofmann C, Pizzagalli F, Boetsch C, Alberati D, Ereshefsky L, Jhee S, Patat A, Boutouyrie-Dumont B, Martin-Facklam M (2016) Effects of the glycine reuptake inhibitors bitopertin and RG7118 on glycine in cerebrospinal fluid: results of two proofs of mechanism studies in healthy volunteers. Psychopharmacology 233:2429\u20132439","journal-title":"Psychopharmacology"},{"key":"5276_CR79","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/nyas.12547","volume":"1338","author":"W Hu","year":"2015","unstructured":"Hu W, MacDonald ML, Elswick DE, Sweet RA (2015) The glutamate hypothesis of schizophrenia: evidence from human brain tissue studies. Ann N Y Acad Sci 1338:38\u201357","journal-title":"Ann N Y Acad Sci"},{"key":"5276_CR80","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1159\/000445556","volume":"38","author":"B Huang","year":"2016","unstructured":"Huang B, Xie Q, Lu X, Qian T, Li S, Zhu R, Yu W, Chen G, Chen Z, Xu X (2016) GlyT1 inhibitor NFPS exerts neuroprotection via GlyR alpha1 subunit in the rat model of transient focal cerebral ischaemia and reperfusion. Cell Physiol Biochem 38:1952\u20131962","journal-title":"Cell Physiol Biochem"},{"key":"5276_CR81","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1007\/s40618-021-01720-3","volume":"45","author":"M Imenshahidi","year":"2022","unstructured":"Imenshahidi M, Hossenzadeh H (2022) Effects of glycine on metabolic syndrome components: a review. J Endocrinol Invest 45:927\u2013939","journal-title":"J Endocrinol Invest"},{"key":"5276_CR82","doi-asserted-by":"crossref","unstructured":"Javitt DC (2012) Glycine transport inhibitors in the treatment of schizophrenia. In: Novel antischizophrenia treatments. pp 367\u2013399","DOI":"10.1007\/978-3-642-25758-2_12"},{"key":"5276_CR83","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1176\/ajp.151.8.1234","volume":"151","author":"DC Javitt","year":"1994","unstructured":"Javitt DC, Zylberman I, Zukin SR, Heresco-Levy U, Lindenmayer J-P (1994) Amelioration of negative symptoms in schizophrenia by glycine. Am J Psychiatry 151:1234\u20131236","journal-title":"Am J Psychiatry"},{"key":"5276_CR84","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1111\/jnc.15145","volume":"157","author":"K Jayaraman","year":"2021","unstructured":"Jayaraman K, Das AK, Luethi D, Szollosi D, Schutz GJ, Reith MEA, Sitte HH, Stockner T (2021) SLC6 transporter oligomerization. J Neurochem 157:919\u2013929","journal-title":"J Neurochem"},{"key":"5276_CR85","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1046\/j.1471-4159.1996.67010336.x","volume":"67","author":"F Jursky","year":"1996","unstructured":"Jursky F, Nelson N (1996) Developmental expression of the glycine transporters GLYT1 and GLYT2 in mouse brain. J Neurochem 67:336\u2013344","journal-title":"J Neurochem"},{"key":"5276_CR86","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.brainres.2010.03.032","volume":"1331","author":"M Kalinichev","year":"2010","unstructured":"Kalinichev M, Starr KR, Teague S, Bradford AM, Porter RA, Herdon HJ (2010) Glycine transporter 1 (GlyT1) inhibitors exhibit anticonvulsant properties in the rat maximal electroshock threshold (MEST) test. Brain Res 1331:105\u2013113","journal-title":"Brain Res"},{"key":"5276_CR87","doi-asserted-by":"crossref","unstructured":"Karpycheva SA, Ivontsin LA, Mashkovtseva EV, Nartsissov YR (2025) Molecular modeling of glycine and ions binding to the Glyt1 transporter. Journal of Innovative Solutions for Eco-Environmental Sustainability 109\u2013109","DOI":"10.46991\/JISEES.2025.SI1.109"},{"key":"5276_CR88","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/0165-6147(93)90108-V","volume":"14","author":"JA Kemp","year":"1993","unstructured":"Kemp JA, Leeson PD (1993) The glycine site of the NMDA receptor\u2014five years on. Trends Pharmacol Sci 14:20\u201325","journal-title":"Trends Pharmacol Sci"},{"key":"5276_CR89","doi-asserted-by":"publisher","first-page":"7586","DOI":"10.1523\/JNEUROSCI.23-20-07586.2003","volume":"23","author":"GG Kinney","year":"2003","unstructured":"Kinney GG, Sur C, Burno M, Mallorga PJ, Williams JB, Figueroa DJ, Wittmann M, Lemaire W, Conn PJ (2003) The glycine transporter type 1 inhibitor N-[3-(4\u2032-fluorophenyl)-3-(4\u2032-phenylphenoxy) propyl] sarcosine potentiates NMDA receptor-mediated responses in vivo and produces an antipsychotic profile in rodent behavior. J Neurosci 23:7586\u20137591","journal-title":"J Neurosci"},{"key":"5276_CR90","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/j.bcp.2010.07.004","volume":"80","author":"K Kopec","year":"2010","unstructured":"Kopec K, Flood DG, Gasior M, McKenna BAW, Zuvich E, Schreiber J, Salvino JM, Durkin JT, Ator MA, Marino MJ (2010) Glycine transporter (GlyT1) inhibitors with reduced residence time increase prepulse inhibition without inducing hyperlocomotion in DBA\/2 mice. Biochem Pharmacol 80:1407\u20131417","journal-title":"Biochem Pharmacol"},{"key":"5276_CR91","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s11094-016-1438-6","volume":"50","author":"D Korablina","year":"2016","unstructured":"Korablina D, Vorozhtsov N, Sviridova L, Kalenikova E, Medvedev O (2016) Pharmacological activity of 4, 5-dihydropyrazole derivatives. Pharm Chem J 50:281\u2013295","journal-title":"Pharm Chem J"},{"key":"5276_CR92","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s00221-022-06530-4","volume":"241","author":"A Kumar","year":"2023","unstructured":"Kumar A, Akhtar A, Kuhad A, Sah SP (2023) Sarcosine (glycine transporter inhibitor) attenuates behavioural and biochemical changes induced by ketamine, in the rat model of schizophrenia. Exp Brain Res 241:451\u2013467","journal-title":"Exp Brain Res"},{"key":"5276_CR93","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1126\/science.add7150","volume":"379","author":"T Laboute","year":"2023","unstructured":"Laboute T, Zucca S, Holcomb M, Patil DN, Garza C, Wheatley BA, Roy RN, Forli S, Martemyanov KA (2023) Orphan receptor GPR158 serves as a metabotropic glycine receptor: mGlyR. Science 379:1352\u20131358","journal-title":"Science"},{"key":"5276_CR94","doi-asserted-by":"publisher","DOI":"10.3390\/ph16111535","volume":"16","author":"AD Ladagu","year":"2023","unstructured":"Ladagu AD, Olopade FE, Adejare A, Olopade JO (2023) GluN2A and GluN2B N-methyl-D-aspartate receptor (NMDARs) subunits: their roles and therapeutic antagonists in neurological diseases. Pharmaceuticals 16:1535","journal-title":"Pharmaceuticals"},{"key":"5276_CR95","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1017\/S1461145709990939","volume":"13","author":"H-Y Lane","year":"2010","unstructured":"Lane H-Y, Lin C-H, Huang Y-J, Liao C-H, Chang Y-C, Tsai GE (2010) A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia. Int J Neuropsychopharmacol 13:451\u2013460","journal-title":"Int J Neuropsychopharmacol"},{"key":"5276_CR96","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.coph.2005.11.002","volume":"6","author":"SM Lechner","year":"2006","unstructured":"Lechner SM (2006) Glutamate-based therapeutic approaches: inhibitors of glycine transport. Curr Opin Pharmacol 6:75\u201381","journal-title":"Curr Opin Pharmacol"},{"key":"5276_CR97","doi-asserted-by":"publisher","first-page":"373","DOI":"10.4103\/1673-5374.228711","volume":"13","author":"RH Lee","year":"2018","unstructured":"Lee RH, Lee MH, Wu CY, e Silva AC, Possoit HE, Hsieh T-H, Minagar A, Lin HW (2018) Cerebral ischemia and neuroregeneration. Neural Regen Res 13:373\u2013385","journal-title":"Neural Regen Res"},{"key":"5276_CR98","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1007\/PL00000899","volume":"58","author":"P Legendre","year":"2001","unstructured":"Legendre P (2001) The glycinergic inhibitory synapse. Cell Mol Life Sci 58:760\u2013793","journal-title":"Cell Mol Life Sci"},{"key":"5276_CR99","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-57613-z","volume":"16","author":"N Li","year":"2025","unstructured":"Li N, Wei Y, Li R, Meng Y, Zhao J, Bai Q, Wang G, Zhao Y (2025) Modulation of the human GlyT1 by clinical drugs and cholesterol. Nat Commun 16:2412","journal-title":"Nat Commun"},{"key":"5276_CR100","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s00702-017-1685-z","volume":"124","author":"HH Lido","year":"2017","unstructured":"Lido HH, Jonsson S, Hyytia P, Ericson M, Soderpalm B (2017) Further characterization of the GlyT-1 inhibitor Org25935: anti-alcohol, neurobehavioral, and gene expression effects. J Neural Transm (Vienna) 124:607\u2013619","journal-title":"J Neural Transm (Vienna)"},{"key":"5276_CR101","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1111\/j.1369-1600.2011.00367.x","volume":"17","author":"HH Lid\u00f6","year":"2012","unstructured":"Lid\u00f6 HH, Marston H, Ericson M, S\u00f6derpalm B (2012) The glycine reuptake inhibitor Org24598 and acamprosate reduce ethanol intake in the rat; tolerance development to acamprosate but not to Org24598. Addict Biol 17:897\u2013907","journal-title":"Addict Biol"},{"key":"5276_CR102","doi-asserted-by":"publisher","first-page":"357","DOI":"10.3109\/15622975.2015.1117654","volume":"18","author":"C-Y Lin","year":"2017","unstructured":"Lin C-Y, Liang S-Y, Chang Y-C, Ting S-Y, Kao C-L, Wu Y-H, Tsai GE, Lane H-Y (2017) Adjunctive sarcosine plus benzoate improved cognitive function in chronic schizophrenia patients with constant clinical symptoms: a randomised, double-blind, placebo-controlled trial. World J Biol Psychiatry 18:357\u2013368","journal-title":"World J Biol Psychiatry"},{"key":"5276_CR103","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/0014-5793(92)80875-H","volume":"305","author":"Q-R Liu","year":"1992","unstructured":"Liu Q-R, Nelson H, Mandiyan S, L\u00f3pez-Corcuera B, Nelson N (1992) Cloning and expression of a glycine transporter from mouse brain. FEBS Lett 305:110\u2013114","journal-title":"FEBS Lett"},{"key":"5276_CR104","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1038\/aps.2009.105","volume":"30","author":"X-q Liu","year":"2009","unstructured":"Liu X-q, Sheng R, Qin Z-h (2009) The neuroprotective mechanism of brain ischemic preconditioning. Acta Pharmacol Sin 30:1071\u20131080","journal-title":"Acta Pharmacol Sin"},{"key":"5276_CR105","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1042\/bst0290742","volume":"29","author":"B Lopez-Corcuera","year":"2001","unstructured":"Lopez-Corcuera B, Aragon C, Geerlings A (2001) Regulation of glycine transporters. Biochem Soc Trans 29:742\u2013745","journal-title":"Biochem Soc Trans"},{"key":"5276_CR106","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/978-3-319-55769-4_2","volume":"16","author":"B Lopez-Corcuera","year":"2017","unstructured":"Lopez-Corcuera B, Benito-Munoz C, Aragon C (2017) Glycine transporters in glia cells: structural studies. Adv Neurobiol 16:13\u201332","journal-title":"Adv Neurobiol"},{"key":"5276_CR107","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1046\/j.1471-4159.1998.71052211.x","volume":"71","author":"B L\u00f3pez\u2010Corcuera","year":"1998","unstructured":"L\u00f3pez\u2010Corcuera B, Mart\u00ednez\u2010Maza R, N\u00fa\u00f1ez E, Roux M, Supplisson S, Ar Arag\u00f3n C (1998) Differential properties of two stably expressed brain\u2010specific glycine transporters. J Neurochem 71:2211\u20132219","journal-title":"J Neurochem"},{"key":"5276_CR108","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.neuint.2012.07.005","volume":"61","author":"Y Lu","year":"2012","unstructured":"Lu Y, Zhang J, Ma B, Li K, Li X, Bai H, Yang Q, Zhu X, Ben J, Chen Q (2012) Glycine attenuates cerebral ischemia\/reperfusion injury by inhibiting neuronal apoptosis in mice. Neurochem Int 61:649\u2013658","journal-title":"Neurochem Int"},{"key":"5276_CR109","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/S0028-3908(03)00227-2","volume":"45","author":"PJ Mallorga","year":"2003","unstructured":"Mallorga PJ, Williams JB, Jacobson M, Marques R, Chaudhary A, Conn PJ, Pettibone DJ, Sur C (2003) Pharmacology and expression analysis of glycine transporter GlyT1 with [3H]-(N-[3-(4\u2032-fluorophenyl)-3-(4\u2032 phenylphenoxy) propyl]) sarcosine. Neuropharmacology 45:585\u2013593","journal-title":"Neuropharmacology"},{"key":"5276_CR110","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.neubiorev.2020.07.025","volume":"118","author":"BL Marques","year":"2020","unstructured":"Marques BL, Oliveira-Lima OC, Carvalho GA, de Almeida Chiarelli R, Ribeiro RI, Parreira RC, da Madeira Freitas EM, Resende RR, Klempin F, Ulrich H, Gomez RS, Pinto MCX (2020) Neurobiology of glycine transporters: from molecules to behavior. Neurosci Biobehav Rev 118:97\u2013110","journal-title":"Neurosci Biobehav Rev"},{"key":"5276_CR111","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1113\/jphysiol.2004.063321","volume":"557","author":"M Martina","year":"2004","unstructured":"Martina M, Gorfinkel Y, Halman S, Lowe JA, Periyalwar P, Schmidt CJ, Bergeron R (2004) Glycine transporter type 1 blockade changes NMDA receptor-mediated responses and LTP in hippocampal CA1 pyramidal cells by altering extracellular glycine levels. J Physiol 557:489\u2013500","journal-title":"J Physiol"},{"key":"5276_CR112","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1038\/npp.2012.212","volume":"38","author":"M Martin-Facklam","year":"2013","unstructured":"Martin-Facklam M, Pizzagalli F, Zhou Y, Ostrowitzki S, Raymont V, Bra\u0161i\u0107 JR, Parkar N, Umbricht D, Dannals RF, Goldwater R (2013) Glycine transporter type 1 occupancy by bitopertin: a positron emission tomography study in healthy volunteers. Neuropsychopharmacology 38:504\u2013512","journal-title":"Neuropsychopharmacology"},{"key":"5276_CR113","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.130111","volume":"4","author":"A Matte","year":"2019","unstructured":"Matte A, Federti E, Winter M, Koerner A, Harmeier A, Mazer N, Tomka T, Di Paolo ML, Defalco L, Andolfo I (2019) Bitopertin, a selective oral GLYT1 inhibitor, improves anemia in a mouse model of \u03b2-thalassemia. JCI Insight 4:e130111","journal-title":"JCI Insight"},{"key":"5276_CR114","doi-asserted-by":"publisher","DOI":"10.1016\/j.mam.2025.101360","volume":"103","author":"N Mizzi","year":"2025","unstructured":"Mizzi N, Blundell R (2025) Glycine receptors: structure, function, and therapeutic implications. Mol Aspects Med 103:101360","journal-title":"Mol Aspects Med"},{"key":"5276_CR115","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.3390\/ijms22052479","volume":"22","author":"A Mohammadzadeh","year":"2021","unstructured":"Mohammadzadeh A, Lakatos PP, Balogh M, Z\u00e1dor F, Kar\u00e1di D\u00c1, Z\u00e1dori ZS, Kir\u00e1ly K, Galambos AR, Barsi S, Riba P (2021) Pharmacological evidence on augmented antiallodynia following systemic co-treatment with GlyT-1 and GlyT-2 inhibitors in rat neuropathic pain model. Int J Mol Sci 22:2479","journal-title":"Int J Mol Sci"},{"key":"5276_CR116","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/j.bcp.2011.02.003","volume":"81","author":"H M\u00f6hler","year":"2011","unstructured":"M\u00f6hler H, Boison D, Singer P, Feldon J, Pauly-Evers M, Yee BK (2011) Glycine transporter 1 as a potential therapeutic target for schizophrenia-related symptoms: evidence from genetically modified mouse models and pharmacological inhibition. Biochem Pharmacol 81:1065\u20131077","journal-title":"Biochem Pharmacol"},{"key":"5276_CR117","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1124\/jpet.108.136267","volume":"326","author":"K Morita","year":"2008","unstructured":"Morita K, Motoyama N, Kitayama T, Morioka N, Kifune K, Dohi T (2008) Spinal antiallodynia action of glycine transporter inhibitors in neuropathic pain models in mice. J Pharmacol Exp Ther 326:633\u2013645","journal-title":"J Pharmacol Exp Ther"},{"key":"5276_CR118","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s13318-017-0440-z","volume":"43","author":"V Moschetti","year":"2018","unstructured":"Moschetti V, Desch M, Goetz S, Liesenfeld K-H, Rosenbrock H, Kammerer K-P, Wunderlich G, Wind S (2018) Safety, tolerability and pharmacokinetics of oral BI 425809, a glycine transporter 1 inhibitor, in healthy male volunteers: a partially randomised, single-blind, placebo-controlled, first-in-human study. Eur J Drug Metab Pharmacokinet 43:239\u2013249","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"5276_CR119","doi-asserted-by":"crossref","unstructured":"Nascimento LRC, Tambwe PM, Carvalho GAd, Zanchi FB, Neves BJ, Ulrich H, Pinto MCX (2026) In silico analysis of the multitarget potential of GlyT1 inhibitors in SLC6 transporters. Journal of Biomolecular Structure and Dynamics 1\u201324","DOI":"10.1080\/07391102.2026.2618607"},{"key":"5276_CR120","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.neuropharm.2011.04.010","volume":"61","author":"A Nikiforuk","year":"2011","unstructured":"Nikiforuk A, Kos T, Rafa D, Behl B, Bespalov A, Popik P (2011) Blockade of glycine transporter 1 by SSR-504734 promotes cognitive flexibility in glycine\/NMDA receptor-dependent manner. Neuropharmacology 61:262\u2013267","journal-title":"Neuropharmacology"},{"key":"5276_CR121","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1097\/FBP.0b013e32833d419d","volume":"21","author":"H Nishikawa","year":"2010","unstructured":"Nishikawa H, Inoue T, Izumi T, Nakagawa S, Koyama T (2010) SSR504734, a glycine transporter-1 inhibitor, attenuates acquisition and expression of contextual conditioned fear in rats. Behav Pharmacol 21:576\u2013579","journal-title":"Behav Pharmacol"},{"key":"5276_CR122","doi-asserted-by":"publisher","first-page":"746","DOI":"10.2174\/156720512801322564","volume":"9","author":"D Olivares","year":"2012","unstructured":"Olivares D, Deshpande KV, Shi Y, Lahiri KD, Greig HN, Rogers TJ, Huang X (2012) N-methyl D-aspartate (NMDA) receptor antagonists and memantine treatment for Alzheimer\u2019s disease, vascular dementia and Parkinson\u2019s disease. Curr Alzheimer Res 9:746\u2013758","journal-title":"Curr Alzheimer Res"},{"key":"5276_CR123","doi-asserted-by":"publisher","DOI":"10.1007\/s11064-024-04190-0","author":"OC Oliveira-Lima","year":"2024","unstructured":"Oliveira-Lima OC, de Carvalho GA, do Prado Assun\u00e7\u00e3o L, Bail\u00e3o AM, Ulrich H, Marques BL, de Oliveira ACP, Gomez RS, Pinto MCX (2024) GlyT1 inhibition by NFPS promotes neuroprotection in amyloid-\u03b2-induced Alzheimer\u2019s disease animal model. Neurochem Res. https:\/\/doi.org\/10.1007\/s11064-024-04190-0","journal-title":"Neurochem Res"},{"key":"5276_CR124","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s00702-023-02701-x","volume":"131","author":"Y Olsson","year":"2024","unstructured":"Olsson Y, Lido H, Ademar K, Cadeddu D, Ericson M, Soderpalm B (2024) The GlyT1-inhibitor Org 24598 facilitates the alcohol deprivation abolishing and dopamine elevating effects of bupropion + varenicline in rats. J Neural Transm (Vienna) 131:95\u2013106","journal-title":"J Neural Transm (Vienna)"},{"key":"5276_CR125","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1038\/s43587-022-00311-y","volume":"2","author":"R-Y Pan","year":"2022","unstructured":"Pan R-Y, Zhang J, Wang J, Wang Y, Li Z, Liao Y, Liao Y, Zhang C, Liu Z, Song L (2022) Intermittent fasting protects against Alzheimer\u2019s disease in mice by altering metabolism through remodeling of the gut microbiota. Nat Aging 2:1024\u20131039","journal-title":"Nat Aging"},{"key":"5276_CR126","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.cell.2012.06.029","volume":"150","author":"T Papouin","year":"2012","unstructured":"Papouin T, Ladepeche L, Ruel J, Sacchi S, Labasque M, Hanini M, Groc L, Pollegioni L, Mothet JP, Oliet SH (2012) Synaptic and extrasynaptic NMDA receptors are gated by different endogenous coagonists. Cell 150:633\u2013646","journal-title":"Cell"},{"key":"5276_CR127","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.742058","volume":"12","author":"J-C Pei","year":"2021","unstructured":"Pei J-C, Luo D-Z, Gau S-S, Chang C-Y, Lai W-S (2021) Directly and indirectly targeting the glycine modulatory site to modulate NMDA receptor function to address unmet medical needs of patients with schizophrenia. Front Psychiatry 12:742058","journal-title":"Front Psychiatry"},{"key":"5276_CR128","doi-asserted-by":"publisher","first-page":"477","DOI":"10.2533\/chimia.2018.477","volume":"72","author":"E Pinard","year":"2018","unstructured":"Pinard E, Borroni E, Koerner A, Umbricht D, Alberati D (2018) Glycine transporter type I (GlyT1) inhibitor, bitopertin: a journey from lab to patient. Chimia 72:477\u2013477","journal-title":"Chimia"},{"key":"5276_CR129","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-025-06915-7","author":"A Pinna","year":"2025","unstructured":"Pinna A, Pa\u0142asz A (2025) Modulation of glycine transporters as a novel therapeutic strategy in neuropsychiatry. Psychopharmacology. https:\/\/doi.org\/10.1007\/s00213-025-06915-7","journal-title":"Psychopharmacology"},{"key":"5276_CR130","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.neuropharm.2014.10.003","volume":"89","author":"MC Pinto","year":"2015","unstructured":"Pinto MC, Lima IV, da Costa FL, Rosa DV, Mendes-Goulart VA, Resende RR, Romano-Silva MA, de Oliveira AC, Gomez MV, Gomez RS (2015) Glycine transporters type 1 inhibitor promotes brain preconditioning against NMDA-induced excitotoxicity. Neuropharmacology 89:274\u2013281","journal-title":"Neuropharmacology"},{"key":"5276_CR131","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.neuint.2012.06.018","volume":"61","author":"MC Pinto","year":"2012","unstructured":"Pinto MC, Mourao FA, Binda NS, Leite HR, Gomez MV, Massensini AR, Gomez RS (2012) Pharmacological induction of ischemic tolerance in hippocampal slices by sarcosine preconditioning. Neurochem Int 61:713\u2013720","journal-title":"Neurochem Int"},{"key":"5276_CR132","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.neuroscience.2014.04.054","volume":"271","author":"MC Pinto","year":"2014","unstructured":"Pinto MC, Simao F, da Costa FL, Rosa DV, de Paiva MJ, Resende RR, Romano-Silva MA, Gomez MV, Gomez RS (2014) Sarcosine preconditioning induces ischemic tolerance against global cerebral ischemia. Neuroscience 271:160\u2013169","journal-title":"Neuroscience"},{"key":"5276_CR133","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-01064-1","volume":"7","author":"C Qin","year":"2022","unstructured":"Qin C, Yang S, Chu YH, Zhang H, Pang XW, Chen L, Zhou LQ, Chen M, Tian DS, Wang W (2022) Signaling pathways involved in ischemic stroke: molecular mechanisms and therapeutic interventions. Signal Transduct Target Ther 7:215","journal-title":"Signal Transduct Target Ther"},{"key":"5276_CR134","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12071518","author":"L Raiteri","year":"2024","unstructured":"Raiteri L (2024) Interactions involving glycine and other amino acid neurotransmitters: focus on transporter-mediated regulation of release and glycine-glutamate crosstalk. Biomedicines. https:\/\/doi.org\/10.3390\/biomedicines12071518","journal-title":"Biomedicines"},{"key":"5276_CR135","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1111\/j.1471-4159.2010.06802.x","volume":"114","author":"L Raiteri","year":"2010","unstructured":"Raiteri L, Raiteri M (2010) Functional \u2018glial\u2019 GLYT1 glycine transporters expressed in neurons. J Neurochem 114:647\u2013653","journal-title":"J Neurochem"},{"key":"5276_CR136","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.neuint.2007.04.027","volume":"52","author":"L Raiteri","year":"2008","unstructured":"Raiteri L, Stigliani S, Usai C, Diaspro A, Paluzzi S, Milanese M, Raiteri M, Bonanno G (2008) Functional expression of release-regulating glycine transporters GLYT1 on GABAergic neurons and GLYT2 on astrocytes in mouse spinal cord. Neurochem Int 52:103\u2013112","journal-title":"Neurochem Int"},{"key":"5276_CR137","doi-asserted-by":"publisher","first-page":"S87","DOI":"10.1192\/j.eurpsy.2024.224","volume":"67","author":"C Reuteman-Fowler","year":"2024","unstructured":"Reuteman-Fowler C, Blahova Z, Ikezawa S, Marder S, Falkai P, Krystal J (2024) The phase III CONNEX programme assessing the efficacy and safety of iclepertin in patients with schizophrenia: trial design and recruitment update. Eur Psychiatry 67:S87\u2013S88","journal-title":"Eur Psychiatry"},{"key":"5276_CR138","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2024.137715","volume":"826","author":"RI Ribeiro","year":"2024","unstructured":"Ribeiro RI, Carvalho GA, Chiareli RA, de Assis Lima IV, Bellozi PMQ, Oliveira-Lima OC, Giacomelli \u00c1O, Birbrair A, Gomez RS, de Oliveira ACP (2024) Glycine transporter-1 inhibition by NFPS promotes neuroprotection against striatal damage models. Neurosci Lett 826:137715","journal-title":"Neurosci Lett"},{"key":"5276_CR139","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1038\/sj.bjp.0704766","volume":"136","author":"JM Rigo","year":"2002","unstructured":"Rigo JM, Hans G, Nguyen L, Rocher V, Belachew S, Malgrange B, Leprince P, Moonen G, Selak I, Matagne A (2002) The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA-and glycine-gated currents. Br J Pharmacol 136:659\u2013672","journal-title":"Br J Pharmacol"},{"key":"5276_CR140","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1111\/cts.12578","volume":"11","author":"H Rosenbrock","year":"2018","unstructured":"Rosenbrock H, Desch M, Kleiner O, Dorner-Ciossek C, Schmid B, Keller S, Schlecker C, Moschetti V, Goetz S, Liesenfeld KH, Fillon G, Giovannini R, Ramael S, Wunderlich G, Wind S (2018) Evaluation of pharmacokinetics and pharmacodynamics of BI 425809, a novel GlyT1 inhibitor: translational studies. Clin Transl Sci 11:616\u2013623","journal-title":"Clin Transl Sci"},{"key":"5276_CR141","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1124\/jpet.121.001071","volume":"382","author":"H Rosenbrock","year":"2022","unstructured":"Rosenbrock H, Dorner-Ciossek C, Giovannini R, Schmid B, Schuelert N (2022) Effects of the glycine transporter-1 inhibitor iclepertin (BI 425809) on sensory processing, neural network function, and cognition in animal models related to schizophrenia. J Pharmacol Exp Ther 382:223\u2013232","journal-title":"J Pharmacol Exp Ther"},{"key":"5276_CR142","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s00424-013-1410-1","volume":"466","author":"G Rudnick","year":"2014","unstructured":"Rudnick G, Kr\u00e4mer R, Blakely RD, Murphy DL, Verrey F (2014) The SLC6 transporters: perspectives on structure, functions, regulation, and models for transporter dysfunction. Pflugers Arch Eur J Physiol 466:25\u201342","journal-title":"Pflugers Arch Eur J Physiol"},{"key":"5276_CR143","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2022.947563","volume":"16","author":"R Salceda","year":"2022","unstructured":"Salceda R (2022) Glycine neurotransmission: its role in development. Front Neurosci 16:947563","journal-title":"Front Neurosci"},{"key":"5276_CR144","doi-asserted-by":"publisher","first-page":"266","DOI":"10.9740\/mhc.2016.11.266","volume":"6","author":"RW Schmidt","year":"2016","unstructured":"Schmidt RW, Thompson ML (2016) Glycinergic signaling in the human nervous system: an overview of therapeutic drug targets and clinical effects. Ment Health Clin 6:266\u2013276","journal-title":"Ment Health Clin"},{"key":"5276_CR145","doi-asserted-by":"publisher","first-page":"16778","DOI":"10.1523\/JNEUROSCI.3041-12.2013","volume":"33","author":"Y Schmitz","year":"2013","unstructured":"Schmitz Y, Castagna C, Mrejeru A, Lizardi-Ortiz JE, Klein Z, Lindsley CW, Sulzer D (2013) Glycine transporter-1 inhibition promotes striatal axon sprouting via NMDA receptors in dopamine neurons. J Neurosci 33:16778\u201316789","journal-title":"J Neurosci"},{"key":"5276_CR146","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/s41398-022-02096-5","volume":"12","author":"C Schultheis","year":"2022","unstructured":"Schultheis C, Rosenbrock H, Mack SR, Vinisko R, Schuelert N, Plano A, Sussmuth SD (2022) Quantitative electroencephalography parameters as neurophysiological biomarkers of schizophrenia-related deficits: a phase II substudy of patients treated with iclepertin (BI 425809). Transl Psychiatry 12:329","journal-title":"Transl Psychiatry"},{"key":"5276_CR147","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/s41586-021-03274-z","volume":"591","author":"A Shahsavar","year":"2021","unstructured":"Shahsavar A, Stohler P, Bourenkov G, Zimmermann I, Siegrist M, Guba W, Pinard E, Sinning S, Seeger MA, Schneider TR (2021) Structural insights into the inhibition of glycine reuptake. Nature 591:677\u2013681","journal-title":"Nature"},{"key":"5276_CR148","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.neuropharm.2015.08.031","volume":"99","author":"H-Y Shen","year":"2015","unstructured":"Shen H-Y, Van Vliet EA, Bright K-A, Hanthorn M, Lytle NK, Gorter J, Aronica E, Boison D (2015) Glycine transporter 1 is a target for the treatment of epilepsy. Neuropharmacology 99:554\u2013565","journal-title":"Neuropharmacology"},{"key":"5276_CR149","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2020.00097","volume":"13","author":"H-Y Shen","year":"2020","unstructured":"Shen H-Y, Weltha L, Cook JM, Gesese R, Omi W, Baer SB, Rose RM, Reemmer J, Boison D (2020) Sarcosine suppresses epileptogenesis in rats with effects on hippocampal DNA methylation. Front Mol Neurosci 13:97","journal-title":"Front Mol Neurosci"},{"key":"5276_CR150","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1037\/0735-7044.121.5.815","volume":"121","author":"P Singer","year":"2007","unstructured":"Singer P, Boison D, M\u00f6hler H, Feldon J, Yee BK (2007) Enhanced recognition memory following glycine transporter 1 deletion in forebrain neurons. Behav Neurosci 121:815","journal-title":"Behav Neurosci"},{"key":"5276_CR151","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/S1734-1140(10)70279-6","volume":"62","author":"K Soca\u0142a","year":"2010","unstructured":"Soca\u0142a K, Nieoczym D, Rundfeldt C, Wla\u017a P (2010) Effects of sarcosine, a glycine transporter type 1 inhibitor, in two mouse seizure models. Pharmacol Rep 62:392\u2013397","journal-title":"Pharmacol Rep"},{"key":"5276_CR152","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2021.108631","volume":"193","author":"D Stroebel","year":"2021","unstructured":"Stroebel D, Mony L, Paoletti P (2021) Glycine agonism in ionotropic glutamate receptors. Neuropharmacology 193:108631","journal-title":"Neuropharmacology"},{"key":"5276_CR153","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.neuroscience.2024.07.037","volume":"578","author":"S Supplisson","year":"2025","unstructured":"Supplisson S (2025) Dynamic role of GlyT1 as glycine sink or source: Pharmacological implications for the gain control of NMDA receptors. Neuroscience 578:59\u201368","journal-title":"Neuroscience"},{"key":"5276_CR154","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1517\/13543784.13.5.515","volume":"13","author":"C Sur","year":"2004","unstructured":"Sur C, Kinney GG (2004) The therapeutic potential of glycine transporter-1 inhibitors. Expert Opin Investig Drugs 13:515\u2013521","journal-title":"Expert Opin Investig Drugs"},{"key":"5276_CR155","doi-asserted-by":"publisher","first-page":"643","DOI":"10.2174\/138945007780618535","volume":"8","author":"C Sur","year":"2007","unstructured":"Sur C, Kinney GG (2007) Glycine transporter 1 inhibitors and modulation of NMDA receptor-mediated excitatory neurotransmission. Curr Drug Targets 8:643\u2013649","journal-title":"Curr Drug Targets"},{"key":"5276_CR156","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1111\/bjh.17479","volume":"194","author":"AT Taher","year":"2021","unstructured":"Taher AT, Viprakasit V, Cappellini MD, Kraus D, Cech P, Volz D, Winter E, Nave S, Dukart J, Khwaja O (2021) Haematological effects of oral administration of bitopertin, a glycine transport inhibitor, in patients with non-transfusion-dependent \u03b2-thalassaemia. Br J Haematol 194:474\u2013477","journal-title":"Br J Haematol"},{"key":"5276_CR157","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1254\/jphs.10150FP","volume":"113","author":"M Tanabe","year":"2010","unstructured":"Tanabe M, Nitta A, Ono H (2010) Neuroprotection via strychnine-sensitive glycine receptors during post-ischemic recovery of excitatory synaptic transmission in the hippocampus. J Pharmacol Sci 113:378\u2013386","journal-title":"J Pharmacol Sci"},{"key":"5276_CR158","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.biopsych.2003.09.012","volume":"55","author":"G Tsai","year":"2004","unstructured":"Tsai G, Lane H-Y, Yang P, Chong M-Y, Lange N (2004) Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 55:452\u2013456","journal-title":"Biol Psychiatry"},{"key":"5276_CR159","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1001\/jamapsychiatry.2014.163","volume":"71","author":"D Umbricht","year":"2014","unstructured":"Umbricht D, Alberati D, Martin-Facklam M, Borroni E, Youssef EA, Ostland M, Wallace TL, Knoflach F, Dorflinger E, Wettstein JG (2014) Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study. JAMA Psychiatr 71:637\u2013646","journal-title":"JAMA Psychiatr"},{"key":"5276_CR160","doi-asserted-by":"publisher","first-page":"16157","DOI":"10.3390\/ijms232416157","volume":"23","author":"J Wang","year":"2022","unstructured":"Wang J, Liu H, Zhang Y-W (2022) Cross-linking and functional analyses for dimerization of a cysteine mutant of glycine transporter 1. Int J Mol Sci 23:16157","journal-title":"Int J Mol Sci"},{"key":"5276_CR161","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s00726-013-1493-1","volume":"45","author":"W Wang","year":"2013","unstructured":"Wang W, Wu Z, Dai Z, Yang Y, Wang J, Wu G (2013) Glycine metabolism in animals and humans: implications for nutrition and health. Amino Acids 45:463\u2013477","journal-title":"Amino Acids"},{"key":"5276_CR162","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.2174\/138161207781368693","volume":"13","author":"TI Webb","year":"2007","unstructured":"Webb TI, Lynch JW (2007) Molecular pharmacology of the glycine receptor chloride channel. Curr Pharm Des 13:2350\u20132367","journal-title":"Curr Pharm Des"},{"key":"5276_CR163","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2024.02.026","author":"Y Wei","year":"2024","unstructured":"Wei Y, Li R, Meng Y, Hu T, Zhao J, Gao Y, Bai Q, Li N, Zhao Y (2024) Transport mechanism and pharmacology of the human GlyT1. Cell. https:\/\/doi.org\/10.1016\/j.cell.2024.02.026","journal-title":"Cell"},{"key":"5276_CR164","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.1152\/jn.1996.76.5.3415","volume":"76","author":"K Wilcox","year":"1996","unstructured":"Wilcox K, Fitzsimonds RM, Johnson B, Dichter M (1996) Glycine regulation of synaptic NMDA receptors in hippocampal neurons. J Neurophysiol 76:3415\u20133424","journal-title":"J Neurophysiol"},{"key":"5276_CR165","doi-asserted-by":"publisher","first-page":"170","DOI":"10.2174\/156802610790410974","volume":"10","author":"SE Wolkenberg","year":"2010","unstructured":"Wolkenberg SE, Sur C (2010) Recent progress in the discovery of non-sarcosine based GlyT1 inhibitors. Curr Top Med Chem 10:170\u2013186","journal-title":"Curr Top Med Chem"},{"key":"5276_CR166","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.neuroimage.2011.11.052","volume":"75","author":"DF Wong","year":"2013","unstructured":"Wong DF, Ostrowitzki S, Zhou Y, Raymont V, Hofmann C, Borroni E, Kumar A, Parkar N, Bra\u0161i\u0107 JR, Hilton J (2013) Characterization of [11C] RO5013853, a novel PET tracer for the glycine transporter type 1 (GlyT1) in humans. Neuroimage 75:282\u2013290","journal-title":"Neuroimage"},{"key":"5276_CR167","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-023-01163-3","volume":"15","author":"G Wunderlich","year":"2023","unstructured":"Wunderlich G, Blahova Z, Garcia M, Jessen F (2023) Efficacy and safety of the novel GlyT1 inhibitor BI 425809 in Alzheimer\u2019s dementia: a randomized controlled trial. Alzheimers Res Ther 15:24","journal-title":"Alzheimers Res Ther"},{"key":"5276_CR168","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.pharmthera.2008.08.004","volume":"120","author":"CR Yang","year":"2008","unstructured":"Yang CR, Svensson KA (2008) Allosteric modulation of NMDA receptor via elevation of brain glycine and D-serine: the therapeutic potentials for schizophrenia. Pharmacol Ther 120:317\u2013332","journal-title":"Pharmacol Ther"},{"key":"5276_CR169","doi-asserted-by":"publisher","first-page":"3169","DOI":"10.1523\/JNEUROSCI.5120-05.2006","volume":"26","author":"BK Yee","year":"2006","unstructured":"Yee BK, Balic E, Singer P, Schwerdel C, Grampp T, Gabernet L, Knuesel I, Benke D, Feldon J, Mohler H (2006) Disruption of glycine transporter 1 restricted to forebrain neurons is associated with a procognitive and antipsychotic phenotypic profile. J Neurosci 26:3169\u20133181","journal-title":"J Neurosci"},{"key":"5276_CR170","doi-asserted-by":"publisher","DOI":"10.1002\/alz.064468","volume":"18","author":"M Yoo","year":"2022","unstructured":"Yoo M, Kim SM, Lee J, Kim HJ, Park SJ (2022) Withdrawn: glycine transporter 1 (GlyT1) is a novel therapeutic target for Alzheimer\u2019s disease. Alzheimers Dement 18:e064468","journal-title":"Alzheimers Dement"},{"key":"5276_CR171","doi-asserted-by":"publisher","first-page":"3952","DOI":"10.1523\/JNEUROSCI.15-05-03952.1995","volume":"15","author":"F Zafra","year":"1995","unstructured":"Zafra F, Aragon C, Olivares L, Danbolt NC, Gim\u00e9nez C, Storm-Mathisen J (1995a) Glycine transporters are differentially expressed among CNS cells. J Neurosci 15:3952\u20133969","journal-title":"J Neurosci"},{"key":"5276_CR172","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1002\/iub.128","volume":"60","author":"F Zafra","year":"2008","unstructured":"Zafra F, Gimenez C (2008) Glycine transporters and synaptic function. IUBMB Life 60:810\u2013817","journal-title":"IUBMB Life"},{"key":"5276_CR173","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1111\/j.1460-9568.1995.tb01125.x","volume":"7","author":"F Zafra","year":"1995","unstructured":"Zafra F, Gomeza J, Olivares L, Arag\u00f3n C, Gim\u00e9nez C (1995b) Regional distribution and developmental variation of the glycine transporters GLYT1 and GLYT2 in the rat CNS. Eur J Neurosci 7:1342\u20131352","journal-title":"Eur J Neurosci"},{"key":"5276_CR174","doi-asserted-by":"publisher","first-page":"3207","DOI":"10.1113\/jphysiol.2009.168757","volume":"587","author":"HX Zhang","year":"2009","unstructured":"Zhang HX, Hyrc K, Thio LL (2009a) The glycine transport inhibitor sarcosine is an NMDA receptor co-agonist that differs from glycine. J Physiol 587:3207\u20133220","journal-title":"J Physiol"},{"key":"5276_CR175","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.neuropharm.2009.07.019","volume":"57","author":"HX Zhang","year":"2009","unstructured":"Zhang HX, Lyons-Warren A, Thio LL (2009b) The glycine transport inhibitor sarcosine is an inhibitory glycine receptor agonist. Neuropharmacology 57:551\u2013555","journal-title":"Neuropharmacology"},{"key":"5276_CR176","doi-asserted-by":"publisher","first-page":"3525","DOI":"10.1007\/s11064-022-03697-8","volume":"47","author":"Q Zhang","year":"2022","unstructured":"Zhang Q, Jia M, Wang Y, Wang Q, Wu J (2022) Cell death mechanisms in cerebral ischemia\u2013reperfusion injury. Neurochem Res 47:3525\u20133542","journal-title":"Neurochem Res"},{"key":"5276_CR177","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1002\/hipo.22372","volume":"25","author":"X Zhang","year":"2015","unstructured":"Zhang X, Zhang Q, Tu J, Zhu Y, Yang F, Liu B, Brann D, Wang R (2015) Prosurvival NMDA 2 A receptor signaling mediates postconditioning neuroprotection in the hippocampus. Hippocampus 25:286\u2013296","journal-title":"Hippocampus"},{"key":"5276_CR178","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2017431118","author":"YW Zhang","year":"2021","unstructured":"Zhang YW, Uchendu S, Leone V, Bradshaw RT, Sangwa N, Forrest LR, Rudnick G (2021) Chloride-dependent conformational changes in the GlyT1 glycine transporter. Proc Natl Acad Sci U S A. https:\/\/doi.org\/10.1073\/pnas.2017431118","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5276_CR179","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1248\/bpb.b15-00501","volume":"39","author":"J Zhao","year":"2016","unstructured":"Zhao J, Tao H, Xian W, Cai Y, Cheng W, Yin M, Liang G, Li K, Cui L, Zhao B (2016) A highly selective inhibitor of glycine transporter-1 elevates the threshold for maximal electroshock-induced tonic seizure in mice. Biol Pharm Bull 39:174\u2013180","journal-title":"Biol Pharm Bull"},{"key":"5276_CR180","doi-asserted-by":"publisher","DOI":"10.3892\/ijmm.2021.5070","author":"Y Zhao","year":"2022","unstructured":"Zhao Y, Zhang X, Chen X, Wei Y (2022) Neuronal injuries in cerebral infarction and ischemic stroke: from mechanisms to treatment (review). Int J Mol Med. https:\/\/doi.org\/10.3892\/ijmm.2021.5070","journal-title":"Int J Mol Med"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05276-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05276-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05276-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T03:43:38Z","timestamp":1783914218000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-026-05276-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,14]]},"references-count":180,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["5276"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05276-y","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,14]]},"assertion":[{"value":"22 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Clinical trial number: not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"During the preparation of this manuscript, the author(s) used ChatGPT (version 4.0) solely for language editing and grammar refinement. The tool did not contribute to the scientific content, data interpretation, or idea generation. The author(s) subsequently reviewed and revised the manuscript as needed and took full responsibility for the content of the publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"AI-assisted technologies in the writing process"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}